 -- EXPAREL average daily sales at 103 of the prior year for the month of February 2021 -- PARSIPPANY, N.J., March 09, 2021 GLOBE NEWSWIRE -- Pacira BioSciences, Inc. Nasdaq: PCRX, the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited net product sales of EXPAREL bupivacaine liposome injectable suspension and iovera of 35.6 million and 0.7 million, respectively, for the month of February 2021. EXPAREL average daily sales were 103 percent of the prior year for February 2021. 